Tempest Therapeutics Inc expected to post a loss of $3.29 a share - Earnings Preview
05/05/2025 12:15
Tempest Therapeutics Inc TPST.OQ TPST.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for Tempest Therapeutics Inc is for a loss of $3.29 per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Tempest Therapeutics Inc is $65.00, above its last closing price of $6.99. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -3.25 | -3.28 | -4.03 | Missed | -23 |
| Sep. 30 2024 | -4.56 | -4.71 | -5.33 | Missed | -13.3 |
| Jun. 30 2024 | -5.78 | -5.24 | -5.46 | Missed | -4.2 |
| Mar. 31 2024 | -4.98 | -4.86 | -4.68 | Beat | 3.8 |
| Dec. 31 2023 | -4.81 | -5.02 | -4.94 | Beat | 1.5 |
| Sep. 30 2023 | -7.25 | -7.45 | -6.24 | Beat | 16.2 |
| Jun. 30 2023 | -7.15 | -6.73 | -7.02 | Missed | -4.3 |
| Mar. 31 2023 | -8.42 | -8.35 | -7.15 | Beat | 14.4 |
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T